Factors influencing cyclosporine blood concentration-dose ratio

Annals of Pharmacotherapy

Volumn 36, Issue 2, 2002, Pages 193-199

  García Sáiz, Mar ^a   López Gil, Arturo ^b   Alfonso, Itziar ^c   Boada, Jose N ^d   Armijo, Juan A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b Medical affairs Merck sharp and Dohme ltd   (Spain)

^c Unit of Multisystem Trauma   (Spain)

^d HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

Concentration dose ratio; Cyclosporine; Transplantation

Indexed keywords

BILIRUBIN; CHOLESTEROL; CREATININE; CYCLOSPORIN A;

ADULT; AGE; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TRANSPLANTATION;

ADULT; AGE FACTORS; BILIRUBIN; CHOLESTEROL; CREATININE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; MALE; MIDDLE AGED; OBESITY; ORGAN TRANSPLANTATION;

EID: 0036159216     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10380     Document Type: Article

References (28)

1. Pediatric clinical pharmacology of antiepileptic drugs: An especial consideration
2. Correlation between age and plasma level/dosage ratio for phenobarbital in infants and children
3. Plasma levels of primidone and its metabolite phenobarbital: Effects of age and associated therapy
4. Pharmacokinetics of valproic acid in children I. Multiple antiepileptic drug therapy
5. Concentration-dose relationship of antiepileptic drugs in pediatric outpatients during monotherapy: Interindividual variability and influence of age
6. Influence of age and comedication on steady-state carbamazepine serum level-dose ratios in Japanese paediatric patients
7. Vigabatrin serum concentration to dosage ratio: Influence of age and associated antiepileptic drugs
8. Lamotrigine serum concentration-to-dose ratio: Influence of age and concomitant antiepileptic drugs and dosage implications
9. Area under the curve monitoring of cyclosporine therapy: The early posttransplant period
10. The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation
11. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation
12. Factors influencing the pharmacokinetics of cyclosporine in man
13. Cyclosporin clinical pharmacokinetics
14. Clinically significant drug interactions with cyclosporin. An update
15. The obese patient
16. Methods for clinical monitoring of cyclosporin transplant patients
17. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: Report of the consensus panel
18. Importance of cyclosporine dosage and blood levels in simultaneous pancreas and kidney transplant success
19. Pharmacokinetics of cyclosporin A
20. On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers
21. The pharmacokinetics of Sandimmun Neoral: A new oral formulation of cyclosporine
22. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay
23. Effect of age oncyclosporine pharmacokinetics in marrow transplant recipients
24. Influence of posttransplant time on dose and concentration of cyclosporine in renal transplant patients
25. Cross-correlation of cyclosporine concentrations and biochemical measures of kidney and liver function in heart and heart-lung transplant recipients
26. Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: Effects of binding and metabolism
27. Effect of hepatic dysfunction on oral cyclosporine pharmacokinetics in marrow transplant patients
28. Is the plasma lipoprotein pattern of importance for treatment with cyclosporine?